Algernon Announces Enrollment of 100 Patients in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19
September 29, 2020 08:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Provides Update on its Planned Phase II Clinical Trial
November 25, 2019 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, B.C., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development...
Breathtec Announces Closing of Private Placement
October 24, 2018 07:00 ET
|
Breathtec Biomedical Inc.
Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, British Columbia, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical...